1259367-40-2

Upstream product

• 1259278-70-0 (3S)-3-[(2-chloro-5-fluoro-pyrimidin-4-yl)amino]cyclohexanol 
• 1259278-12-0 benzyl N-[(1S,3R)-3-aminocyclohexyl]carbamate 
• 1259278-11-9 benzyl N-[(1S,3R)-3-carbamoylcyclohexyl]carbamate 
• 952616-39-6 (1R,3S)-3-(((benzyloxy)carbonyl)amino)cyclohexanecarboxylic acid 
• 1259278-09-5 ethyl (1R,3S)-3-benzyloxycarbonylaminocyclohexane-1-carboxylate 
• 227783-08-6 (1S,3R)-3-ethoxycarbonylcyclohexane-1-carboxylic acid 
• 1259278-72-2 (S)-3-(2-chloro-5-fluoropyrimidin-4-ylamino)cyclohexanone 

Downstream Products

• 1259367-41-3 (1R,3S)-3-((5-fluoro-2-(5-fluoro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexanol 

Relevant academic research and scientific papers

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

PROBLEM TO BE SOLVED: To provide inhibitors of influenza virus replication. SOLUTION: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient comprise administering to the biological sample or patient an effective amount of a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A compound is represented by structural formula (IA) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. COPYRIGHT: (C)2015,JPO&INPIT